Want to see SE:ACARIX full AI Analyst Report?
Top Page
Acarix AB
(ACARIX)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.20
▼(-27.50% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily held down by very large ongoing operating losses and persistent negative cash flow, implying continued external funding needs despite some improvement. Technicals are neutral-to-weak with price below key longer-term averages and a negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
Positive Factors
Revenue Growth
Revenue is expanding despite the company operating from a small base, indicating increasing adoption of its cardiovascular diagnostic offering. If sustained, this growth can improve operating leverage, broaden commercial reach, and provide a foundation for narrowing losses over the next several quarters.
Negative Factors
Deep Operating Losses
Losses remain exceptionally large relative to revenue, showing that the current cost base is far above the company’s commercial scale. Even with some narrowing versus prior years, this gap makes sustained profitability distant and leaves results highly dependent on substantial revenue growth or cost reduction.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue is expanding despite the company operating from a small base, indicating increasing adoption of its cardiovascular diagnostic offering. If sustained, this growth can improve operating leverage, broaden commercial reach, and provide a foundation for narrowing losses over the next several quarters.
Read all positive factors
Acarix AB (ACARIX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr235.34M
Dividend YieldN/A
Average Volume (3M)1.43M
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth65.82%
EPS Growth41.28%
CountrySE
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,470,018
30 Day Avg. Volume1,431,850
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr19.10M
Acarix AB Business Overview & Revenue Model
Company Description
Acarix AB (publ) is a medical technology company that develops and introduces diagnostic solutions for cardiovascular conditions to markets including Germany, Sweden, the Middle East, Switzerland, Austria, and globally. Their key product is the CA...
How the Company Makes Money
Acarix makes money primarily by selling and/or licensing its CADScor System for clinical use. Revenue is generated from (1) system-related sales to healthcare providers (e.g., devices and associated components) and (2) recurring income tied to usa...
Acarix AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.22M | 7.36M | 6.20M | 6.24M | 5.82M | 3.76M |
| Gross Profit | 5.15M | 2.76M | 5.59M | 5.30M | 4.62M | 2.82M |
| EBITDA | -34.79M | -44.53M | -62.63M | -77.12M | -76.12M | -50.52M |
| Net Income | -39.38M | -48.09M | -66.19M | -77.84M | -76.98M | -51.80M |
Balance Sheet | ||||||
| Total Assets | 47.74M | 48.33M | 80.76M | 62.88M | 69.48M | 118.60M |
| Cash, Cash Equivalents and Short-Term Investments | 28.88M | 18.27M | 53.99M | 35.15M | 11.31M | 15.81M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 251.00K | 523.00K |
| Total Liabilities | 3.96M | 10.16M | 5.06M | 11.00M | 17.66M | 18.06M |
| Stockholders Equity | 43.78M | 38.17M | 75.70M | 51.88M | 51.83M | 100.54M |
Cash Flow | ||||||
| Free Cash Flow | -23.23M | -49.14M | -64.25M | -81.37M | -75.02M | -48.05M |
| Operating Cash Flow | -34.77M | -48.38M | -63.33M | -81.37M | -74.87M | -48.01M |
| Investing Cash Flow | -454.00K | -757.00K | -920.00K | 0.00 | -151.00K | -43.00K |
| Financing Cash Flow | 32.04M | 11.11M | 86.98M | 106.23M | 69.03M | -164.00K |
Acarix AB Technical Analysis
Neutral
0.28
Price Trends
0.23
Negative
0.24
Negative
0.26
Negative
Market Momentum
>-0.01
Negative
47.37
Neutral
60.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.23, and above the 200-day MA of 0.26, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.37 is Neutral, neither overbought nor oversold. The STOCH value of 60.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ACARIX.
Acarix AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr56.62B | 88.75 | 30.26% | 0.45% | 13.94% | 5.70% | |
60 Neutral | kr416.26M | -86.40 | -3.61% | ― | 15.87% | 92.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr539.68M | -64.17 | -2.84% | ― | -13.72% | 52.47% | |
47 Neutral | kr154.66M | -2.57 | -54.68% | ― | ― | ― | |
46 Neutral | kr418.19M | -3.75 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr235.34M | -6.16 | -100.09% | ― | 65.82% | 41.28% |
* Healthcare Sector Average
SE:ACARIX
Acarix AB
0.21
-0.11
-34.48%
SE:SEZI
Senzime AB
2.66
-3.29
-55.29%
SE:BACTI.B
Bactiguard Holding AB
15.40
-5.00
-24.51%
SE:SECT.B
Sectra AB Class B
290.20
-12.58
-4.16%
SE:HEART
Scandinavian Real Heart AB
18.20
-9.90
-35.23%
SE:MNTC
Mentice AB
14.80
4.15
38.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.